Skip to main content Scroll Top

Our highlights from the 11th Annual Microbiome Movement USA Summit 2026

biose-background
biose-background-2
Written by
Biose Industrie USA Team

Biose participated as the Lead Partner of the 11th Annual Microbiome Movement USA Summit (November 10–11, 2026, Boston, MA), which brought together biotechnology companies, pharmaceutical developers, investors, regulatory experts, and academic researchers working in microbiome therapeutics.

Richard Ellis, Global Business Development Director at Biose

Richard Ellis, Global Business Development Director at Biose, delivered a presentation on “LBP & NGP CDMO Support – Bringing Comfort to the Marketplace with Consistent & Repeatable CMC Support for Microbiome Therapeutics & NGPs.” The presentation highlighted Biose’s integrated manufacturing capabilities, from fermentation through finished dosage forms, and its ability to support reliable process development, scale-up, and commercial supply.

The conference focused on rebuilding investor confidence in microbiome therapeutics, demonstrating clinical efficacy, addressing manufacturing challenges, and strengthening regulatory and CMC strategies.

Investor confidence and clinical differentiation

The conference highlighted the continued challenges faced by microbiome companies in securing investment following previous clinical setbacks.

Investors increasingly expect stronger preclinical-to-clinical translation, clearly defined mechanisms of action, credible clinical endpoints, and evidence of manufacturing scalability.

Manufacturing challenges for multi-strain products

Vedanta presented a structured risk-management approach to optimizing the production of complex microbial consortia, using severity, occurrence, and detectability to prioritize process improvements.

Key technical observations included:

  • Lower primary-drying temperatures during lyophilization improved viability in the process presented.
  • Oxygen exposure during certain lyophilization-related steps had limited impact on the specific anaerobic strain studied.
  • Room-temperature stability remained challenging, reinforcing the importance of strain-specific stabilization strategies.

MRM Health also reported improved growth of its strains in coculture compared with monoculture, illustrating potential opportunities for process optimization alongside the added complexity of manufacturing microbial consortia.

These findings highlight the value of early process characterization, lyophilization optimization, and stability assessment.

Analytical methods and regulatory expectations

A dedicated workshop addressed the limitations of conventional methods for assessing identity, viability, and potency in complex microbial products.

Kanvas Biosciences presented HiPR-FISH, an imaging-based approach for identifying and quantifying individual strains within microbial consortia. The method offers potential advantages for strain-level characterization, although equipment requirements and throughput remain a limitation.

During the FDA presentation, Paul Carlson emphasized the importance of product-specific regulatory strategies, early FDA engagement, appropriate safety characterization, and stability data supporting the intended clinical study duration.

Commercialization and regulatory strategy

Discussions highlighted the different commercial models for consumer probiotics and regulated microbiome therapeutics, particularly regarding development costs, timelines, clinical evidence, and market access.

The European regulatory presentation also emphasized differences in stability requirements, excipient acceptability, importation, Qualified Person release, and packaging expectations.

Overall assessment

The conference reinforced Biose’s visibility within the US microbiome therapeutics industry and highlighted opportunities associated with engineered bacteria, multi-strain consortia, novel formulations, and advanced analytical technologies.

Overall, the event reinforced Biose’s opportunity to position itself as an integrated US–Europe CDMO supporting microbiome products from early process development through clinical and commercial manufacturing.